Abstract
BackgroundFive studies were conducted to evaluate a novel oral combination tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™), for efficacy against induced flea infestations, speed of kill and effects on flea reproduction on dogs.MethodsBased on pre-treatment flea counts, dogs were randomly allocated to treatment with a single, oral dose of either placebo or Simparica Trio™ at the minimum label dose of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel (as pamoate salt) on Day 0. All dogs were infested with approximately 100 unfed, adult fleas (C. felis or C. canis) prior to treatment and weekly for 5 weeks post-treatment. In Studies 1, 2 and 3, the number of viable fleas were comb-counted at 24 h after treatment and after each weekly infestation; Study 2 also included groups treated with tablets containing sarolaner-alone (1.2 mg/kg), moxidectin-alone (24 µg/kg) or pyrantel-alone (5 mg/kg). In Study 4, flea counts were conducted at 3, 4, 8 and 12 h after treatment and subsequent weekly infestations to establish speed of kill. In Study 5 (flea reproduction), dogs were housed in an enclosure designed to facilitate collection of flea eggs.ResultsEfficacy of Simparica Trio™ against C. felis was ≥ 99.7% and against C. canis was 100% at 24 h after treatment and after subsequent infestations for at least 35 days. Treatment with sarolaner-alone had similar efficacy to Simparica Trio™, while moxidectin-alone and pyrantel-alone were no different from placebo at most time points. In Study 4, significant flea killing started at 4 h after treatment; by 8 h after treatment, all treated dogs were free of fleas. Following weekly re-infestation, the combination product reduced fleas by ≥ 97.8% within 12 h for 28 days. Simparica Trio™ reduced flea egg-laying by 100% for 35 days. No treatment-related adverse reactions occurred in any study.ConclusionsA single dose of Simparica Trio™ at the recommended minimum dose provided highly efficacious and rapid treatment within 4 h of existing flea infestations and persistent control of fleas on dogs for 5 weeks. The efficacy against fleas resulted in 100% prevention of flea reproduction for over a month following a single oral dose.
Highlights
Five studies were conducted to evaluate a novel oral combination tablet containing sarolaner, moxidectin and pyrantel (Simparica TrioTM), for efficacy against induced flea infestations, speed of kill and effects on flea reproduction on dogs
We report a series of laboratory studies that evaluated the efficacy of Simparica TrioTM at a minimum label dose of 1.2 mg/kg sarolaner, 24 μg/kg moxidectin and 5 mg/kg pyrantel against the most common flea species, C. felis and C. canis, infesting dogs
Flea counts for the combination product were significantly lower (7.78 ≤ tdf ≤ 34.43, 7 ≤ df ≤ 35, P < 0.0001) than the placebo at all counts in all three studies (Tables 1 and 2)
Summary
Five studies were conducted to evaluate a novel oral combination tablet containing sarolaner, moxidectin and pyrantel (Simparica TrioTM), for efficacy against induced flea infestations, speed of kill and effects on flea reproduction on dogs. Dogs can be affected by numerous internal and external parasites which can have direct deleterious effects on their hosts and potentially transmit disease agents to dogs and humans [1, 2]. Flea infestations are very common in dogs but often go unnoticed by pet owners [4] unless the dog develops pruritus or the flea infestation becomes severe, in which case newly emerged fleas may jump on and bite the owner. Due to the ubiquitous nature of fleas, their ability to potentially induce clinical signs such as pruritus, and the possibility of transmitting diseases to the dog including zoonotic disease agents, efficacious treatment and control of flea infestations is a significant concern for pet owners and veterinarians [12]. To alleviate the direct negative impact of fleas and to reduce the risks of disease transmission, year-round flea control should be considered for pets in most geographical areas [3, 13]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
